NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

GUTS

Fractyl Health Inc

Jul 09 • 04:00PM ET

1.53

Dollar change +0.03
Percentage change 2.00	%

Healthcare • Biotechnology • USA • NASD

Peers: ILMN EXAS CDNA PACB TXG TWST GH CYRX QDEL FLGT

| Held by: VTI VTWO VXF IWC VTWG IWM VTWV MSSM IWO IWN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	57.37%	Shs Outstand	48.92M	Perf Week	-3.16%
Market Cap	74.93M	Forward P/E	-	EPS next Y	-1.74	Insider Trans	-0.26%	Shs Float	20.88M	Perf Month	-23.12%
Enterprise Value	94.24M	PEG	-	EPS next Q	-0.36	Inst Own	33.03%	Short Float	11.91%	Perf Quarter	42.99%
Income	-89.11M	P/S	1248.82	EPS this Y	7.82%	Inst Trans	-6.52%	Short Ratio	5.12	Perf Half Y	-30.45%
Sales	0.06M	P/B	11.74	EPS next Y	-16.69%	ROA	-72.28%	Short Interest	2.49M	Perf YTD	-25.73%
Book/sh	0.13	P/C	1.78	EPS next 5Y	7.56%	ROE	-196.81%	52W High	4.92 -68.90%	Perf Year	-65.54%
Cash/sh	0.86	P/FCF	-	EPS past 3/5Y	-8.92% -12.32%	ROIC	-141.87%	52W Low	0.87 75.26%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-1475.00%	Volatility	5.63% 12.47%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1570.65	EPS Y/Y TTM	-	Oper. Margin	-161246.67%	ATR (14)	0.17	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.50	Sales Y/Y TTM	-	Profit Margin	-148511.67%	RSI (14)	41.93	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.50	EPS Q/Q	-359.94%	SMA20	-15.56%	Beta	1.57	Target Price	9.33
Payout	-	Debt/Eq	9.63	Sales Q/Q	-100.00%	SMA50	-14.03%	Rel Volume	0.60	Prev Close	1.50
Employees	107	LT Debt/Eq	8.84	Earnings	May 13 AMC	SMA200	-18.38%	Avg Volume	485.27K	Price	1.53
IPO	Feb 02, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	0.36% -	Trades		Volume	292,429	Change	2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	Morgan Stanley	Overweight	$18
Feb-27-24	Initiated	BofA Securities	Buy	$26

Jun-23-25 07:40AM	Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy (GlobeNewswire) -24.77%
07:30AM	Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models (GlobeNewswire)
Jun-18-25 07:00AM	Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing (GlobeNewswire)
Jun-13-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.07%
07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
07:00AM	Loading…
Jun-04-25 07:00AM	Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide (GlobeNewswire)
May-19-25 07:00AM	Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes (GlobeNewswire) +25.44%
May-17-25 07:15AM	Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 (GlobeNewswire)
May-13-25 04:05PM	Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -13.28%
May-06-25 07:00AM	Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference (GlobeNewswire) -7.98%
Apr-28-25 04:30PM	Fractyl Health to Present Compelling Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire)
Apr-02-25 03:34PM	Fractyl Health, Inc. (GUTS): Insider Were Buying In Q1 2025 (Insider Monkey)
Apr-01-25 07:00AM	Fractyl Health Reports Positive Early Data Showing Revita Has Potential to Prevent Weight Regain After GLP-1 Discontinuation (GlobeNewswire) -6.72%
Mar-03-25 04:05PM	Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire)
Feb-24-25 07:00AM	Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025 (GlobeNewswire)
09:35AM	Loading…
Feb-12-25 09:35AM	After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS) (Zacks)
Feb-10-25 03:00AM	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments (Pharma Voice)
Jan-31-25 08:01AM	Fractyl Health Announces Increased Focus on Groundbreaking Revita Weight Maintenance and Rejuva Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 (GlobeNewswire) -5.15%
Jan-13-25 07:00AM	Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort (GlobeNewswire) +5.41%
Jan-06-25 09:10AM	Heres Why Fractyl Health, Inc. (NASDAQ:GUTS) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) -6.36%
Dec-12-24 07:00AM	Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Dec-09-24 07:00AM	Fractyl Health to Present New Preclinical Data from its Rejuva Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-26-24 07:00AM	Fractyl Health to Participate in the Upcoming December Conferences (GlobeNewswire)
Nov-12-24 04:05PM	Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-04-24 04:05PM	Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek 2024 (GlobeNewswire) -9.86% -6.25%
07:00AM	Fractyl Health Presented New Analysis from Pooled Data of Revita Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek 2024 (GlobeNewswire)
Oct-29-24 07:00AM	Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 (GlobeNewswire) +23.19%
Oct-28-24 07:00AM	Fractyl Health to Present Compelling Weight Maintenance Data from both Revita and Rejuva Platforms at ObesityWeek 2024 (GlobeNewswire) +16.46%
Sep-24-24 07:00AM	Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-03-24 07:00AM	Fractyl Health to Participate in Upcoming September Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-14-24 04:05PM	Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +5.38%
Aug-12-24 10:53AM	Rising diabetes rates spur growth in weight management solutions (Medical Device Network) +14.61%
Aug-08-24 12:13PM	Fractyl Health touts positive year-long weight loss results for Revita device (Clinical Trials Arena) -6.19%
08:00AM	Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita Endoscopic Procedure (GlobeNewswire)
Aug-07-24 07:00AM	Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 (GlobeNewswire) -9.77%
Jul-30-24 07:00AM	Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs (GlobeNewswire)
Jun-25-24 09:02AM	FDA expands Fractyl endoscopy trial to include untreated diabetes patients (Medical Device Network) -9.22%
07:00AM	Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day (GlobeNewswire)
Jun-24-24 06:00AM	Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates (GlobeNewswire) +5.76%
Jun-23-24 01:30PM	Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-29-24 07:00AM	Fractyl Health to Present New Preclinical Obesity Data from Rejuva Platform at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM	GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace) +8.52%
04:00PM	Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM	Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM	Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
May-08-24 06:00AM	Fractyl Health to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 06:00AM	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 (GlobeNewswire)
Apr-30-24 08:38AM	Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting (GlobeNewswire)
Apr-17-24 03:10PM	The 3 Most Volatile Stocks for Short-Term Traders: April 2024 (InvestorPlace)
Apr-02-24 08:00AM	Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes (GlobeNewswire) -9.53%
Apr-01-24 07:00AM	Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs (GlobeNewswire)
Mar-12-24 02:06PM	UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire) -10.34%
08:38AM	Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire)
Mar-03-24 01:13PM	Analysts Bet Big on These Beaten-Down IPO Stocks (TipRanks)
Feb-20-24 08:38AM	Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita Pivotal Clinical Trials (GlobeNewswire)
Feb-01-24 08:08PM	Fractyl Health Announces Pricing of Initial Public Offering (GlobeNewswire)

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Royan Ajay	Director	Mar 14 '25	Buy	1.28	17,901	22,980	17,901	Mar 18 07:57 PM
Barnes Kelly Ann	Director	Mar 14 '25	Buy	1.30	31,000	40,210	31,000	Mar 18 04:50 PM
SCHULMAN AMY W	Director	Mar 13 '25	Buy	1.17	8,550	9,964	8,550	Mar 17 05:09 PM
BRADLEY WILLIAM	Director	Mar 13 '25	Buy	1.26	16,129	20,358	16,129	Mar 17 02:57 PM
Conaway Samuel	Director	Mar 13 '25	Buy	1.17	8,550	9,964	8,550	Mar 17 02:56 PM
Rajagopalan Harith	Chief Executive Officer	Jan 31 '25	Option Exercise	1.70	90,972	154,652	582,301	Feb 03 06:04 PM
Rajagopalan Harith	Chief Executive Officer	Jan 30 '25	Option Exercise	1.70	20,948	35,612	512,277	Feb 03 06:04 PM
Rajagopalan Harith	Chief Executive Officer	Jan 31 '25	Sale	1.82	90,972	165,205	491,329	Feb 03 06:04 PM
Rajagopalan Harith	Chief Executive Officer	Jan 30 '25	Sale	1.95	20,948	40,798	491,329	Feb 03 06:04 PM
Caplan Jay David	President, Chief Product Off.	Jan 31 '25	Option Exercise	1.70	22,346	37,988	175,890	Feb 03 06:03 PM
Caplan Jay David	President, Chief Product Off.	Jan 30 '25	Option Exercise	1.70	21,472	36,502	175,016	Feb 03 06:03 PM
Caplan Jay David	President, Chief Product Off.	Jan 30 '25	Sale	1.95	21,472	41,802	153,544	Feb 03 06:03 PM
Caplan Jay David	President, Chief Product Off.	Jan 31 '25	Sale	1.81	22,346	40,464	153,544	Feb 03 06:03 PM
HARITH RAJAGOPALAN	Director	Jan 30 '25	Proposed Sale	2.02	111,920	226,078		Jan 30 04:12 PM
JAY CAPLAN	Officer	Jan 30 '25	Proposed Sale	2.02	43,818	88,512		Jan 30 04:12 PM
Rajagopalan Harith	Chief Executive Officer	Nov 10 '24	Option Exercise	0.00	216,924	0	587,846	Nov 13 06:26 PM
Rajagopalan Harith	Chief Executive Officer	Nov 11 '24	Sale	2.47	96,517	238,358	491,329	Nov 13 06:26 PM
Caplan Jay David	President, Chief Product Off.	Nov 10 '24	Option Exercise	0.00	187,257	0	217,741	Nov 13 06:25 PM
Caplan Jay David	President, Chief Product Off.	Nov 11 '24	Sale	2.47	64,197	158,541	153,544	Nov 13 06:25 PM
Caplan Jay David	President, Chief Product Off.	Sep 12 '24	Option Exercise	1.70	95,484	162,323	95,484	Sep 13 06:39 PM
Caplan Jay David	President, Chief Product Off.	Sep 12 '24	Sale	2.90	65,000	188,474	30,484	Sep 13 06:39 PM
JAY D CAPLAN	Officer	Sep 12 '24	Proposed Sale	2.85	65,000	185,213		Sep 12 04:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GUTS

Fractyl Health Inc

Upgrade your FINVIZ experience